Drug Design Principles for Peptide Therapeutics
From SAR to ADMET -- the core principles of rational drug design applied to peptide-based therapeutics.
From Molecule to Medicine
Designing a peptide drug requires understanding how molecular structure translates to biological activity, how the body processes the molecule, and how to optimize a starting compound into a viable therapeutic. This article covers the core principles.
Structure-Activity Relationship (SAR)
Structure-Activity Relationship (SAR) is the study of how specific structural features of a molecule relate to its biological activity. For peptides, this means systematically modifying individual amino acids and measuring the effect on potency, selectivity, and stability.
A typical SAR workflow:
- Start with a bioactive peptide (natural or discovered through screening)
- Synthesize analogs with systematic substitutions at each position
- Test each analog for activity
- Identify which residues are critical for binding (the pharmacophore) and which can be modified to improve drug-like properties
Example: In the development of luteinizing hormone-releasing hormone (LHRH) agonists, replacing the natural glycine at position 6 with a D-amino acid dramatically increased potency and resistance to enzymatic degradation.
The Pharmacophore Concept
A pharmacophore is the minimal set of structural features — not atoms, but functional groups and their spatial arrangement — that a molecule must possess to bind its biological target and produce a therapeutic effect.
Key pharmacophore elements include:
- Hydrogen bond donors and acceptors
- Hydrophobic centers (aromatic rings, aliphatic chains)
- Positive or negative charge centers
- Specific spatial distances and angles between these features
For peptide drugs, the pharmacophore is often a short sequence of three to five critical residues presented in a specific three-dimensional orientation.
Lead Optimization
Once a lead compound (a molecule with promising but imperfect activity) is identified, it undergoes lead optimization to improve multiple properties simultaneously:
- Potency: Increase binding affinity (lower IC50 or Ki)
- Selectivity: Reduce off-target interactions
- Stability: Resist proteolytic degradation
- Solubility: Ensure adequate aqueous solubility
- Bioavailability: Optimize absorption and distribution
ADMET Properties
Every drug candidate must satisfy ADMET criteria:
| Property | What It Measures | Why It Matters |
|---|---|---|
| Absorption | How the drug enters the bloodstream | Determines route of administration |
| Distribution | Where the drug goes in the body | Determines target tissue exposure |
| Metabolism | How the body chemically modifies the drug | Affects duration of action and toxicity |
| Excretion | How the body eliminates the drug | Determines dosing frequency |
| Toxicity | Harmful effects on biological systems | Determines safety and therapeutic window |
Peptide drugs face unique ADMET challenges: they are often poorly absorbed orally, rapidly degraded by proteases, and cleared quickly from the body.
Peptide Drug Modifications
Medicinal chemists use several strategies to overcome these challenges:
- Cyclization: Connecting the N-terminus to the C-terminus (or side chains) with a covalent bridge. Cyclized peptides are more resistant to proteases and often have improved receptor selectivity. Examples: cyclosporine, oxytocin.
- D-amino acid substitution: Replacing natural L-amino acids with their D-enantiomers. Proteases recognize L-amino acids specifically, so D-substitutions block enzymatic degradation.
- PEGylation: Attaching polyethylene glycol (PEG) chains to the peptide. This increases hydrodynamic radius, reduces renal clearance, shields from proteases, and can improve solubility.
- N-methylation: Replacing backbone NH with N-CH3 groups. This removes a hydrogen bond donor (improving membrane permeability) and blocks proteolytic cleavage.
- Backbone modification: Incorporating peptidomimetics such as beta-amino acids, peptoids, or N-acyl bonds.
FDA-Approved Peptide Drugs
| Drug | Year Approved | Indication | Notable Feature |
|---|---|---|---|
| Oxytocin | 1956 | Labor induction | Cyclic nonapeptide |
| Insulin | 1982 | Diabetes | Recombinant first biologic approved |
| Cyclosporine | 1983 | Immunosuppression | Cyclic undecapeptide |
| Leuprolide | 1985 | Prostate cancer | GnRH agonist, D-amino acid at position 6 |
| Octreotide | 1987 | Acromegaly | Somatostatin analog, cyclic |
| Desmopressin | 1990 | Diabetes insipidus | Modified vasopressin analog |
| Buserelin | 1991 | Prostate cancer | GnRH agonist |
| Nesiritide | 2001 | Heart failure | Recombinant B-type natriuretic peptide |
| Exenatide | 2005 | Type 2 diabetes | GLP-1 receptor agonist, D-amino acids |
| Liraglutide | 2010 | Type 2 diabetes / Obesity | GLP-1 analog, fatty acid acylation for albumin binding |
| Semaglutide | 2017 | Type 2 diabetes / Obesity | GLP-1 analog, PEGylation + albumin binding |
| Eptinezumab | 2020 | Migraine prevention | Anti-CGRP monoclonal antibody (peptide-derived) |
Key Takeaway
Peptide drug design balances potency, selectivity, and drug-like properties. The same structural modifications that improve metabolic stability can alter binding affinity — so every change must be evaluated in the context of the full ADMET profile.
Summary
| Concept | Core Idea |
|---|---|
| SAR | Map structure to activity through systematic modifications |
| Pharmacophore | Minimal 3D arrangement of functional groups for binding |
| Lead optimization | Iterative improvements to potency, selectivity, and drug properties |
| ADMET | Absorption, Distribution, Metabolism, Excretion, Toxicity |
| Cyclization | Improves stability and selectivity |
| D-amino acids | Blocks protease recognition |
| PEGylation | Extends half-life, improves solubility |